Evidence map›Paper›PMID 25563358›Full record

ArticleJournal of personalized medicine2014

Next generation sequencing as an aid to diagnosis and treatment of an unusual pediatric brain cancer.

John Glod, Mihae Song, Archana Sharma, Rachana Tyagi, Roy H Rhodes, David J Weissmann, Sudipta Roychowdhury, Atif Khan, Michael P Kane, Kim Hirshfield and 3 more

Open access · goldAbstract read
In one paragraph

Article in Journal of personalized medicine, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
0.2field-weighted citation impact, top 47% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 1 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 3 institutions in 1 country.

John GlodRutgers Cancer Institute of New Jersey, 195 Little Albany Street, New Brunswick, NJ 08903, USA. john.glod@nih.gov.
Mihae SongRutgers Robert Wood Johnson Medical School, 125 Paterson Street, New Brunswick, NJ 08901, USA. songm2@rwjms.rutgers.edu.
Archana SharmaRutgers Cancer Institute of New Jersey, 195 Little Albany Street, New Brunswick, NJ 08903, USA. sharmaar@cinj.rutgers.edu.
Rachana TyagiRutgers Robert Wood Johnson Medical School, 125 Paterson Street, New Brunswick, NJ 08901, USA. tyagira@rwjms.rutgers.edu.
Roy H RhodesRutgers Robert Wood Johnson Medical School, 1 Robert Wood Johnson Place-MEB 212, New Brunswick, NJ 08903, USA. rhodesrh@rwjms.rutgers.edu.
David J WeissmannRutgers Robert Wood Johnson Medical School, 1 Robert Wood Johnson Place-MEB 212, New Brunswick, NJ 08903, USA. weissmdj@rwjms.rutgers.edu.
Sudipta RoychowdhuryUniversity Radiology Group, 579-A Cranbury Road, East Brunswick, NJ 08816, USA. sr10@comcast.net.
Atif KhanRutgers Cancer Institute of New Jersey, 195 Little Albany Street, New Brunswick, NJ 08903, USA. khanat@cinj.rutgers.edu.
Michael P KaneRutgers Cancer Institute of New Jersey, 195 Little Albany Street, New Brunswick, NJ 08903, USA. kanemp@cinj.rutgers.edu.
Kim HirshfieldRutgers Cancer Institute of New Jersey, 195 Little Albany Street, New Brunswick, NJ 08903, USA. hirshfie@cinj.rutgers.edu.
Shridar GanesanRutgers Cancer Institute of New Jersey, 195 Little Albany Street, New Brunswick, NJ 08903, USA. ganesash@cinj.rutgers.edu.
Robert S DiPaolaRutgers Cancer Institute of New Jersey, 195 Little Albany Street, New Brunswick, NJ 08903, USA. dipaolrs@cinj.rutgers.edu.
Lorna Rodriguez-RodriguezRutgers Cancer Institute of New Jersey, 195 Little Albany Street, New Brunswick, NJ 08903, USA. rodriglo@cinj.rutgers.edu.
Rutgers, The State University of New Jersey · USRutgers Cancer Institute of New JerseyUniversity Radiology · US

Funding

TRANSCRIPTIONAL PROFILINGP30CA072720 · NCI · UNIV OF MED/DENT NJ-R W JOHNSON MED SCH · PI Chang S Chan · 1997 to 2026
$94.5M
NCI NIH HHS P30 CA072720
6 · The paper itself

Abstract

Classification of pediatric brain tumors with unusual histologic and clinical features may be a diagnostic challenge to the pathologist. We present a case of a 12-year-old girl with a primary intracranial tumor. The tumor classification was not certain initially, and the site of origin and clinical behavior were unusual. Genomic characterization of the tumor using a Clinical Laboratory Improvement Amendment (CLIA)-certified next-generation sequencing assay assisted in the diagnosis and translated into patient benefit, albeit transient. Our case argues that next generation sequencing may play a role in the pathological classification of pediatric brain cancers and guiding targeted therapy, supporting additional studies of genetically targeted therapeutics.

Identifiers

PMID25563358
PMCPMC4263965
OpenAlexW2000764635

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.